Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Gender:

Age:

Location:

 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.


Alabama

Research Site
Mobile Alabama 36608

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

California

Research Site
Los Angeles California 90033

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Colorado

Research Site
Denver Colorado 80218

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More »

Rocky Mountain Cancer Centers
Denver Colorado 80218

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Florida

Research Site
Fort Myers Florida 33916

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
St Petersburg Florida 33705

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More »

H. Lee Moffitt Cancer Center
Tampa Florida 33602

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Illinois

Research Site
Chicago Illinois 60601

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Maryland

Johns Hopkins University
Baltimore Maryland 21231

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Massachusetts

Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

New Jersey

Research Site
Hackensak New Jersey 07601

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

New York

North Shore-LIJ Health System Monter Cancer Center
Lake Success New York 11020

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Columbia University Medical Center
New York New York 10032

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

North Dakota

Ohio

Research Site
Cincinati Ohio 45242

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
Cleveland Ohio 44195

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More »

Cleveland Clinic Foundation
Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Tennessee

Research Site
Chattanooga Tennessee 37404

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
Nashville Tennessee 37203

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More »

Sarah Cannon Research Institute
Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Texas

Research Site
Dallas Texas 75246

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
Houston Texas 77030

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
San Antonio Texas 78229

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More »

The University of Texas, MD Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Texas Oncology
Tyler Texas 75702

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Virginia

Virginia Oncology Associates
Norfolk Virginia 23502

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Washington

Yakima Valley Memorial Hospital/North Star Lodge
Yakima Washington 98902

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

West Virginia

West Virginia University - Clinical Trials Research Unit
Morgantown West Virginia 26506

E2905: Randomized Phase III Trial Comparing the frequency of Major Erythroid Response to Treatment with Lenolidomide Alone and in Combination with Epoetin Alfa in Subjects with Low or Intermediate 1 Risk MDS and Symptomatic Anemia

France

Centre Hospitalier Universitaire Hôpital Avicenne
Bobigny 93009

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

CHRU de Lille -Hôpital Claude Huriez Service des Maladies du Sang
Lille 59037

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

CHU De Nantes
Nanes 44000

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Centre de Recherche en Cancerologie de Marseille- Institute Paoli Calmettes
Rouen 13273

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Centre Henri Becquerel
Rouen Cedex 1 76038

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

View More »

CHU Purpan
Toulouse 31059

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS